Loading patent…
AssigneeZeneca Limited
InventorsMichael Samuel Rose, Christopher Boot, Clive Graham Copley, Douglas Stephen Paterson, Susan Margaret Hall, Andrew Firman Wright, David Charles Blakey
Estimating the term…
Antibodies which recognize a tumor related antigen designated CA55.1 such as hybridoma 55.1 deposited as ECACC deposit no. 93081901 in which the complementarity determining regions have the following sequences: a) heavy chain CDR1 G Y W I H (SEQ ID NO: 27) CDR2 E V N P S T G R S D Y N E K F K N (SEQ ID NO: 28) CDR3 E R A Y G Y D D A M D Y (SEQ ID NO: 29) b) light chain CDR1 K S S Q S L L N S R T R K N Y L A (SEQ ID NO: 30) CDR2 W A S T R T S (SEQ ID NO: 31) CDR3 K Q S Y T L R T (SEQ ID NO: 32) or a conservative analogue thereof. The peptide ACEHRGSGWC (SEQ ID NO: 26), as displayed on the surface of bacteriophage NCIMB No. 40638, is a mimic of the tumor related antigen CA55.1.
An antigen binding structure having complementarity determining regions (CDRs) recognising antigen CA55.1 in which the CDRs have the following sequences:
An antigen binding structure having the following structure:
Hybridoma 55.1 deposited as ECACC deposit no. 93081901, variant cell lines thereof or antibody produced thereby.
ACEHRGSGWC phage deposited as NCIMB No. 40638 and variants thereof.
A method of making monoclonal antibody 55.1 comprising:
Dependencies are inferred from the claim text.